

## AC Immune to Present New Data from Alpha-Synuclein and TDP-43 Programs at the AD/PD™ 2021 Virtual Conference

**Lausanne, Switzerland, February 24, 2021** – AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that four new data presentations will be delivered at the 15<sup>th</sup> International Conference on Alzheimer's & Parkinson's Diseases (AD/PD™), taking place virtually from March 9–14, 2021. The presentations will highlight preclinical results from the Company's wholly-owned therapeutic and diagnostic programs targeting pathological forms of alpha-synuclein and TAR DNA-binding protein 43 (TDP-43) for neurodegenerative diseases.

The presentations will showcase how AC Immune's expertise in discovery, assay development and characterization of promising candidates powers its industry-leading pipeline. Two oral presentations will highlight the Company's first-in-class positron emission tomography (PET) imaging agent and therapeutic antibody programs targeting TDP-43 proteinopathies, and two electronic poster presentations will focus on AC Immune's novel small molecule aggregation inhibitor and clinical-stage PET imaging agent for alpha-synuclein.

**Prof. Andrea Pfeifer, CEO of AC Immune SA, commented:** “Our presentations at AD/PD™ further demonstrate how we leverage our Morphomer™ and SupraAntigen™ platforms to generate highly differentiated candidates and enable our precision medicine approach to neurodegenerative diseases. We are advancing proprietary therapeutics in unison with first-in-class companion diagnostics, such as our novel alpha-synuclein PET tracer candidate, ACI-12589, which is being evaluated in an ongoing [First-in-Human study](#). Our unique combination of highly selective diagnostic and therapeutic candidates could allow optimal targeting of key proteinopathies and enable major advances in areas of unmet medical need.”

### Scientific updates at AD/PD™ 2021

#### Morphomer™ TDP-43 imaging

Title: Discovery of PET tracers for TDP-43 proteinopathies

Date: Thursday, March 11, 2021 | 10:45 – 11:00 am CET

Presenter: Oral presentation by Tamara Seredenina

#### Anti-TDP-43 antibody

Title: TDP-43 antibody directed microglial clearance and inhibition of seeded aggregation mitigates neuropathology in models of TDP-43 proteinopathy

Date: Thursday, March 11, 2021 | 11:15 – 11:30 am CET

Presenter: Oral presentation by Tariq Afroz

### Morphomer™ alpha-synuclein imaging

Title: [18F]ACI-12589, a novel alpha-synuclein radiotracer as a biomarker in patients with Parkinson's disease and other synucleinopathies

E-poster ID: P531 / #868

Presenter: E-poster presentation by Efthymia Vokali

### Morphomer™ alpha-synuclein small molecule aggregation inhibitor

Title: Generating a first-in-class inhibitor to treat Parkinson's disease by targeting intracellular alpha-synuclein pathology

E-poster ID: P425 / #1195

Presenter: E-poster presentation by Nadine Ait-Bouziad

### **About AC Immune SA**

AC Immune SA is a Nasdaq-listed clinical-stage biopharmaceutical company, which aims to become a global leader in precision medicine for neurodegenerative diseases. The Company utilizes two proprietary platforms, SupraAntigen™ and Morphomer™, to design, discover and develop small molecule and biological therapeutics as well as diagnostic products intended to diagnose, prevent and modify neurodegenerative diseases caused by misfolding proteins. The Company's pipeline features nine therapeutic and three diagnostic product candidates, with six currently in clinical trials. It has collaborations with major pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company and Janssen Pharmaceuticals.

### **For further information, please contact:**

#### **Head of Investor Relations**

Joshua Drumm, Ph.D.

AC Immune

Phone: +1 917 809 0814

Email: [joshua.drumm@acimmune.com](mailto:joshua.drumm@acimmune.com)

#### **US Media**

Katie Gallagher

LaVoie Health Science

Phone: +1 617 792 3937

Email: [kgallagher@lavoiehealthscience.com](mailto:kgallagher@lavoiehealthscience.com)

#### **European Investors & Media**

Chris Maggos

LifeSci Advisors

Phone: +41 79 367 6254

Email: [chris@lifesciadvisors.com](mailto:chris@lifesciadvisors.com)

### **Forward looking statements**

This press release contains statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune's strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "potential," "outlook" or "continue," and other comparable

terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions "Item 3. Key Information – Risk Factors" and "Item 5. Operating and Financial Review and Prospects" in AC Immune's Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.